# ELDN — Eledon Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ELDN  
**Sources:** 19  
**Published:** 2026-10-25  
**Canonical:** https://app.k3vl4r.com/research/deep-research-eldn-eledon-pharmaceuticals-inc-catalysts-narrative-risk-9149

---

## Eleon Pharmaceuticals, Inc. (Nasdaq: ELDN) — Company Context

Eleon is a clinical-stage biotechnology company headquartered in Irvine, California, developing immune-modulating therapies. Its lead investigational product is **tegoprubart**, an anti-CD40L antibody, targeting organ transplant rejection (kidney, liver, islet cell, xenotransplantation) and ALS [[1]](https://markets.businessinsider.com/news/stocks/eledon-pharmaceuticals-announces-presentation-at-the-american-society-of-nephrology-kidney-week-2026-annual-meeting-1036598924), [[2]](https://markets.businessinsider.com/news/stocks/eledon-pharmaceuticals-announces-presentation-at-the-international-congress-of-the-transplantation-society-1036531628), [[19]](https://eledon.com/). The company is not yet profitable [[18]](https://quartr.com/companies/eledon-pharmaceuticals-inc_13781). The prior-calendar event of an **earnings release on 2026-11-13** is largely corroborated by the new sources below, with one caveat noted later.

## Key Recent Catalysts (roughly July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-eldn-eledon-pharmaceuticals-inc-catalysts-narrative-risk-9149 (free to sign up)._
